Xing Wu

Xing Wu

Auto-generated profile, based on publicly available information

Xing Wu

Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
SHSusu Han
Susu Han
THTao Huang
Tao Huang
WLWen LI
Wen LI
XWXiyu Wang
Xiyu Wang
XWXing Wu
Xing Wu
WYWang Yao
Wang Yao
Objective: Cancer stem cell marker CD44 and its variant isoforms (CD44v) may be correlated with tumor growth, metastasis and chemo-radiotherapy resistance. However, the prognostic power of CD44 and CD44v in advanced cancer remains controversial. Therefore, the purpose of our study was to generalize the prognostic significance of these cancer stem cell markers in advanced cancer patients. Methods: Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from multivariable analysis to assess the associations among CD44, CD44v6, and CD44v9 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Trial sequential analysis (TSA) was also conducted. Results: We included 15 articles that reported on 1,201 patients with advanced cancer (CD44: nine studies with 796 cases, CD44v6: three studies with 143 cases, and CD44v9: three studies with 262 cases). CD44 expression was slightly linked to worse OS (HR = 2.03, P = 0.027), but there was no correlation between CD44 expression and DFS, RFS, or PFS. Stratified analysis showed that CD44 expression was not correlated with OS at ≥ 5 years or OS in patients receiving adjuvant therapy. CD44v6 expression was not associated with OS. CD44v9 expression was closely associated with poor 5-year CSS in patients treated with chemo/radiotherapy (HR = 3.62, P < 0.001). However, TSA suggested that additional trials were needed to confirm these conclusions. Conclusions: CD44 or CD44v9 might be novel therapeutic targets for improving the treatment of advanced cancer patients. Additional prospective clinical trials are strongly needed across different cancer types.

1 January 2019 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
PDF file
SHSusu Han
Susu Han
THTao Huang
Tao Huang
XWXing Wu
Xing Wu
XWXiyu Wang
Xiyu Wang
WLWen Li
Wen Li
WYWang Yao
Wang Yao
Novel prognostic markers and therapeutic targets for advanced cancer are urgently needed. This report with trial sequential analysis (TSA) was first conducted to provide robust estimates of the correlation between aldehyde dehydrogenase 1 (ALDH1) and Nestin and clinical outcomes of advanced cancer patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) were summarized for overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), relapse/recurrence-free survival (RFS), and metastasis-free survival (MFS) from multivariable analysis. TSA was performed to control for random errors. A total of 20 studies with 2050 patients (ALDH1: 15 studies with 1557 patients and Nestin: 5 studies with 493 patients) were identified. ALDH1 (HR = 2.28, p < 0.001) and Nestin (HR = 2.39, p < 0.001) were associated with a worse OS, as confirmed by TSA. Nestin positivity was linked to a poor PFS (HR = 2.08, p < 0.001), but ALDH1 was not linked to DFS, RFS, MFS, or PFS, and TSA showed that more studies were needed. Subgroup analysis by tumor type indicated that ALDH1 positivity may be associated with shorter OS in breast, head and neck cancers, but there was no association with colorectal cancer. Subgroup analysis by study source showed that ALDH1 positivity was correlated with a worse OS for Japanese (HR = 1.94, p = 0.002) and European patients (HR = 4.15, p < 0.001), but there was no association for Chinese patients. Subgroup analysis by survival rate showed that ALDH1 positivity correlated with poor OS at ⩾ 5 years (HR = 2.33, p < 0.001) or 10 years (HR = 1.76, p = 0.038). ALDH1 may be more valuable as an effective therapeutic target than Nestin for improving the long-term survival rate of advanced cancer. Additional prospective clinical trials are needed across different cancer types.

1 September 2024 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
GZGuoxia Zhou
Guoxia Zhou
YYYuecheng Yang
Yuecheng Yang
YZYunkui Zhang
Yunkui Zhang
CPCongxia Pan
Congxia Pan
XWXing Wu
Xing Wu
JZJun Zhang
Jun Zhang
Objective: To investigate the efficacy of ultrasound-guided interscalene brachial plexus block in the treatment of shoulder pain following hepatectomy. Design: A randomized controlled trial. Methods: We conducted a single-center, randomized controlled trial. Forty-four patients with shoulder pain scores of at least 5 were randomly assigned to two groups: the treatment group, which received 0.5% ropivacaine (5mL) combined with dexamethasone (5 mg) (n=22), and the control group, which received normal saline (5mL) (n=22). The intervention was performed in the postanesthesia care unit after shoulder pain was identified by using the visual analogue scale. The shoulder pain was re-evaluated 15 minutes after intervention. The incidence of effective pain relief, defined as at least 75% reduction in pain intensity, was the primary outcome. Secondary outcomes included shoulder pain intensity within 2 days after surgery, the timing of the first rescue analgesia, total additional analgesic use, arterial oxygen saturation, intervention-related adverse reactions, and patient satisfaction regarding shoulder pain. Results: The incidence of effective pain relief was significantly higher in the treatment group compared to the control group (15 (68.2%) vs 2 (9.1%), P< 0.001). The interscalene brachial plexus block not only prolonged the time to first analgesic request (P < 0.001), but also reduced the number of analgesic requests (P < 0.001). In the comparison between groups, arterial oxygen saturation was lower in the control group than that in the treatment group, attributed to the use of sufentanil for remedial analgesia (92.4% vs 94.5%, P=0.014). Conclusion: Interscalene brachial plexus block can effectively relieve post-hepatectomy shoulder pain without clinically significant hypoxemia.

1 August 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
HLHuanyu Luo
Huanyu Luo
YYYuecheng Yang
Yuecheng Yang
ZHZhiyong He
Zhiyong He
CPCongxia Pan
Congxia Pan
XWXing Wu
Xing Wu
JZJun Zhang
Jun Zhang
Objective: This study aims to evaluate the efficacy of esketamine as an epidural adjuvant in mitigating postoperative pain, particularly following the discontinuation of epidural analgesia in patients undergoing open surgery for gynecological malignancies. Design: A randomized controlled trial. Methods: Eighty-eight patients were randomized to receive either esketamine (0.4 mg/kg) combined with sufentanil and ropivacaine (eskatamine group) or sufentanil and ropivacaine alone (control group) via patient-controlled epidural analgesia. Primary outcomes included pain scores on postoperative day 3, assessed using the numeric rating scale. Secondary outcomes included pain scores on postoperative days 1 to 4, Quality of Recovery-15 scores, rescue analgesic requirements, and adverse events. Results: The eskatamine group demonstrated a significant reduction in nocturnal pain intensity on postoperative day 2 compared with controls (median 3.0 vs 4.0, P = 0.044), with fewer patients requiring rescue analgesics on postoperative day 3 (13.4% vs 32.6%, P = 0.036). However, no significant differences were observed in rest pain, movement pain, or breakthrough pain across postoperative day 1– 4. Subgroup analysis revealed higher Recovery-15 scores for moderate pain in the esketamine group (median 10 vs 9, P = 0.048). Transient dizziness was more frequent in the esketamine group (47.7% vs 23.3%, P = 0.017), but no persistent adverse effects were observed. Conclusion: Esketamine, as an adjuvant in patient-controlled epidural analgesia, reduced nocturnal pain on postoperative day 2, shorten the moderate pain duration and lower rescue analgesics within 24 hours after the removal of analgesia device. However, it did not affect pain scores although less rescue analgesia was needed on postoperative day 3.